Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDP in Advanced Malignant Tumors
NCT03908814Phase 1Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lesabelimab in cancer, sponsored by Dragonboat Biopharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerable Dose at 28 days. Started Apr 2019; status: completed.
02
Drugs
lesabelimab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03908814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03908814.